Related Experiment Video
Updated: Mar 2, 2026
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
Antiangiogenic agents and their promising potential in combined therapy
1Division of Hematology/Oncology, Department of Internal Medicine, Davis Medical Center, University of California, 1508 Alhambra Boulevard, Sacramento, CA 95816, USA.
Abstract:
One of the most promising strategies for treating cancer is the addition of antiangiogenic therapy to therapeutic regimens. Angiogenesis, or the growth of new blood vessels from preexisting vessels, is essential both for the growth of a primary tumor and for successful metastasis. As a result of intense research in this field, a number of antiangiogenic agents have been identified and have demonstrated varying degrees of success in inhibiting the growth of solid tumors and metastases in preclinical and clinical studies. The real potential of antiangiogenic agents for cancer therapy resides in strategic combinations with each other, with chemotherapy, with radiation, and with tumor-targeting agents, such as radioimmunotherapy. Along with this new opportunity to develop synergistic therapy comes the challenging complexities of the physiologic systems regulating angiogenesis. These multifaceted systems could intimidate investigators seeking to take advantage of the potential synergy in combined cancer therapy. To aid in these efforts, this overview of key antiangiogenic agent mechanisms, combination strategies and initial studies of the potential synergy with chemotherapy, radiation and radioimmunotherapy is presented.
Insights
Antiangiogenic therapy, which inhibits new blood vessel growth, shows promise for cancer treatment. Combining antiangiogenic agents with chemotherapy, radiation, or radioimmunotherapy may enhance effectiveness against tumors and metastasis.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Angiogenesis (new blood vessel growth) is crucial for primary tumor growth and metastasis.
- Antiangiogenic agents are being developed to inhibit tumor vascularization.
- Previous research has identified several antiangiogenic agents with varying success.
Purpose of the Study:
- To provide an overview of antiangiogenic agent mechanisms.
- To discuss combination strategies for enhanced cancer therapy.
- To present initial studies on the synergy of antiangiogenic agents with chemotherapy, radiation, and radioimmunotherapy.
Main Methods:
- Literature review of antiangiogenic agent mechanisms.
- Analysis of preclinical and clinical studies on antiangiogenic therapies.
- Exploration of combination strategies and potential synergistic effects.
Main Results:
- Numerous antiangiogenic agents have been identified.
- These agents show potential in inhibiting tumor growth and metastasis.
- Strategic combinations offer enhanced therapeutic opportunities.
Conclusions:
- Antiangiogenic therapy is a promising cancer treatment strategy.
- Combining antiangiogenic agents with other therapies (chemotherapy, radiation, radioimmunotherapy) may yield synergistic effects.
- Understanding angiogenesis regulation is key to optimizing combination therapies.
More Related Videos
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
09:03Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells
Published on: November 23, 2014
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:10Mechanism of Angiogenesis
01:24Regulation of Angiogenesis and Blood Supply
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Tumor Immunotherapy
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...